Cancer Policy China has outpaced the U.S. in novel cancer drug approvals since 2023, Friends analysis shows July 24, 2026Vol.52 No.29By Jacquelyn Cobb
Cancer Policy HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud July 24, 2026Vol.52 No.29By Jacquelyn Cobb
Cancer Policy HHS joins Trump’s drive to use AI to address chronic disease July 24, 2026Vol.52 No.29By Claire Marie Porter
Cancer Policy NBCC’s open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act July 24, 2026Vol.52 No.29By Jacquelyn Cobb
Cancer Policy House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role July 17, 2026Vol.52 No.28By Claire Marie Porter
Cancer Policy White House regulatory priorities include “aggressive” HHS agenda July 17, 2026Vol.52 No.28By Jacquelyn Cobb
Cancer Policy HHS cancels fourth USPSTF meeting in a row July 17, 2026Vol.52 No.28By Claire Marie Porter
Cancer Policy FDA halts public release of Complete Response Letters, following citizen petition July 10, 2026Vol.52 No.27By Claire Marie Porter
Cancer Policy Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds July 10, 2026Vol.52 No.27By Sara Willa Ernst
Cancer Policy CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy July 10, 2026Vol.52 No.27By Claire Marie Porter
